The estimated Net Worth of Marc Rubin is at least $1.42 Milione dollars as of 21 February 2019. Marc Rubin owns over 51,185 units of Titan Pharmaceuticals, (de) stock worth over $76,461 and over the last 14 years he sold TTNP stock worth over $759,109. In addition, he makes $585,379 as Executive Chairman of the Board e Chief Executive Officer at Titan Pharmaceuticals, (de).
Marc has made over 12 trades of the Titan Pharmaceuticals, (de) stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 51,185 units of TTNP stock worth $308,134 on 21 February 2019.
The largest trade he's ever made was buying 400,000 units of Titan Pharmaceuticals, (de) stock on 21 September 2018 worth over $100,000. On average, Marc trades about 16,425 units every 70 days since 2010. As of 21 February 2019 he still owns at least 13,581 units of Titan Pharmaceuticals, (de) stock.
You can see the complete history of Marc Rubin stock trades at the bottom of the page.
Dr. Marc Rubin M.D. serves as Executive Chairman of the Board, Chief Executive Officer of the Company. He served as our President and Chief Executive from October 2007 until December 2008 and was re-engaged as our Executive Chairman in May 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG since joining us in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of increasing responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College. Dr. Rubin currently serves on the board of directors of Curis Inc. and Galectin Therapeutics. Based on Dr. Rubin’s position as our Executive Chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board.
As the Executive Chairman of the Board e Chief Executive Officer of Titan Pharmaceuticals, (de), the total compensation of Marc Rubin at Titan Pharmaceuticals, (de) is $585,379. There are no executives at Titan Pharmaceuticals, (de) getting paid more.
Marc Rubin is 65, he's been the Executive Chairman of the Board e Chief Executive Officer of Titan Pharmaceuticals, (de) since 2020. There are 4 older and 3 younger executives at Titan Pharmaceuticals, (de). The oldest executive at Titan Pharmaceuticals, Inc. (de) is M. David MacFarlane, 79, who is the Independent Director.
Marc's mailing address filed with the SEC is 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over $4,610,001 worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth $2,558,794 . The most active insiders traders include David E.Activist Investing ..., James R Mcnab e Marc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of $2,815,253. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth $4,610,001.
titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include: